Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mometasone eluting resorbable scaffold - Lyra Therapeutics

Next Previous
Drug Profile

Mometasone eluting resorbable scaffold - Lyra Therapeutics

Alternative Names: LYR-210; LYR-220; Mometasone furoate sinus drug depot

Latest Information Update: 11 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 480 Biomedical
  • Developer Lyra Therapeutics
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorinated hydrocarbons; Furans; Glucocorticoids; Phenanthrenes; Pregnadienediols; Skin disorder therapies; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Rhinosinusitis

Most Recent Events

  • 02 Jun 2025 Efficacy and adverse events data from phase III ENLIGHTEN II trial in Rhinosinusitis released by Lyra Therapeutics
  • 02 Jun 2025 Pooled efficacy data from phase III ENLIGHTEN I and ENLIGHTEN II trial in Rhinosinusitis released by Lyra Therapeutics
  • 02 Apr 2025 Lyra Therapeutics completes the phase III ENLIGHTEN 2 trial for Rhinosinusitis (In adults, In the elderly) in Belgium, Bulgaria, Germany, Hungary, Poland, USA (Intranasal) (NCT05295459)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top